KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma

Cancer Genomics and Proteomics

Volumn 9, Issue 1, 2012, Pages 51-54

  Wiedl, Thomas ^a,b   Collaud, Steṕhane ^a   Hillinger, Sven ^a   Arni, Stephan ^a   Burgess, Chris ^c   Kroll, Werner ^c   Schraml, Peter ^a   Soltermann, Alex ^a   Moch, Holger ^a   Weder, Walter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Activity based proteomics; KRAS; Lung adenocarcinoma; Myeloblastin

Indexed keywords

MYELOBLASTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; ONCOGENE K RAS; PROTEOMICS; TUMOR BIOPSY;

RATTUS;

EID: 84855404212     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Liaw YP, Huang YC and Lien GW: Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model. BMC Public Health 5: 22, 2005.
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
3. Bos JL: Ras Oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
4. Vakiani E and Solit DB: KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 223: 219-229, 2011.
5. Roberts PJ, Stinchcombe TE, Der CJ and Socinski MA: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28: 4769-4777, 2010.
6. Sangle GV, Zhao R, Mizuno TM and Shen GX: Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Endocrinology 151: 4455-4466, 2010.
7. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A and Donner H (German-Austrian Acute Myeloid Leukemia Study Group): Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008. (Pubitemid 351620111)
8. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359: 1367-1380, 2008.
9. Webb JD and Simon MC: Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle 9: 4098-4105, 2010.
10. Jessani N, Niessen S, Wei BQ, Nicolau M, Humphrey M, Ji Y, Han W, Noh DY, Yates JR 3rd, Jeffrey SS and Cravatt BF: A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods 2: 691-697, 2005. (Pubitemid 41223096)
11. Wiedl T, Ami S, Roschitzki B, Grossmann J, Collaud S, Soltermann A, Hillinger S, Aebersold R and Weder W: Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J Proteomics 74: 1884-1894, 2011.
12. Pearce M, Cullinan A, Hogg G, Hosseini D and Ehrich M: Mutation profiling in tumor samples using the Sequenom OncoCarta™ Panel. Nature Methods 6: vii-viii, 2009.
13. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saarela M, Skotheim RI, Björkman M, Mpindi JP, Haapa-Paananen S, Vainio P, Edgren H, Wolf M, Astola J, Nees M, Hautaniemi S and Kallioniemi O: Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 9: R139, 2008.
14. Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z and Cayre YE: Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59: 959-968, 1989. (Pubitemid 20024607)
15. Owen CA: Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int J Biochem Cell Biol 40: 1246-1272, 2008.
16. Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, Scanni A and Broggini M: Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 22: 235-237, 2011.